Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript
Omeros Corporation ( OMER ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Gregory Demopulos - Co-Founder, Chairman, CEO & President David Borges - VP of Finance, Chief Accounting Officer & Treasurer Nadia Dac - VP & Chief Commercial Officer Conference Call Participants Jennifer Williams Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Stephen Brozak - WBB Securities, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation.
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to diversify beyond semaglutide amid recent headwinds.
Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Catherine A. Melfi - Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems David J.
Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)
Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster
Omeros' recent convertible note exchange highlights severe liquidity issues and questionable creditworthiness, leading to a sharp stock decline. Despite reducing near-term debt obligations, Omeros faces a significant cash burn, with only $52.5 million in cash as of March 2025. The company's cash runway is dangerously short, likely lasting only until late summer 2025, necessitating urgent financial action.
Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Jennifer Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman & CEO David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Steven Whitaker - VP, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcome to today's Earnings Call for Omeros Corporation. At this time, all participants are in listen-only mode.
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings
Omeros Corporation OMER will release its fourth-quarter financial results after the closing bell on Monday, March 31.
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues.
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab.
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald Serge Belanger - Needham & Company Operator Good afternoon, and welcome to today's conference call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President-Clinical Development Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
